(Q37806328)

23 August 2017

0 references

Switching cholinesterase inhibitors in older adults with dementia (English)

1 reference

23 August 2017

0 references

Fadi Massoud

1

1 reference

23 August 2017

Julie Eve Desmarais

series ordinal

2

1 reference

23 August 2017

Serge Gauthier

series ordinal

3

1 reference

23 August 2017

publication date

3 November 2010

1 reference

International Psychogeriatrics

23 August 2017

published in

1 reference

23 August 2017

volume

23

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

372-378

1 reference

Rivastigmine in the treatment of Alzheimer's disease: an update

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Changes in brain cholinesterases in senile dementia of Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Update on the Pharmacological Treatment of Alzheimers Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Neurobiology of butyrylcholinesterase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

A population-based study of cholinesterase inhibitor use for dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Switching from donepezil to galantamine: a double-blind study of two wash-out periods

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Galantamine extended release in Alzheimer's disease: profile report

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

Management of mild to moderate Alzheimer’s disease and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

An examination of self-reported chronic conditions and health status in the 2001 Medicare Health Outcomes Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610210001985

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1017/S1041610210001985

1 reference

23 August 2017

1 reference